Copy to clipboard 
We estimate the trauma segment generated $9.6 billion in worldwide sales during 2025, growing 5.8% compared to the prior year. The segment makes up 15% of the overall orthopedic market.
For the second consecutive year, core trauma exceeded expectations, while procedure volume softness impacted the foot and ankle segment. We expect those two factors to normalize over the coming years but to continue driving mid-single digit growth through 2029.
Below we take a look at 2025 company performance, how companies new to the trauma space are building a base of business, the rise of non-metal implants and ways that companies are filling gaps in niche areas.
Company Performance
Trauma is an extremely consolidated market. Stryker and J&J MedTech are the top two players, accounting for 60% of global sales.
Johnson & Johnson MedTech’s trauma business is more than three times larger than the next largest player, Zimmer Biomet, which benefited from the early-2025 acquisition of Paragon 28. Smith+Nephew and Acumed round up the market’s top five players, who account for a combined 80% of the market.
Like other players in the foot and ankle market, Stryker had a softer year for sales. However, the company’s success in core trauma more than offset the slowdown in foot and ankle. The Pangea Plating System not only drove sales growth but also increased customer awareness of Stryker’s broad trauma offering.
DePuy Synthes’ trauma product growth improved each quarter, with the second half of the year performing far stronger than the first. International sales and the VOLT Plating System were key growth drivers.
Among mid-tier companies, Zimmer Biomet worked through its Paragon 28 integration during 2025. The company had to address “contract friction” but remains bullish on the long-term growth prospects for the business.
“I wanted to buy a company that had innovation today, but a pipeline for tomorrow,” said Zimmer Biomet CEO Ivan Tornos. “We are stabilizing some of the early contract friction that you can see in this category. We continue to see great momentum with commercial execution and launching new products. We think of this asset as something that needs to be growing in double digits for a period of time. There may be some hiccups every once in a while. But overall, the organic growth of Paragon 28 should remain in the teens.”
Smith+Nephew saw good growth from the EVOS plating system, which was partially offset by slower sales of legacy systems. In late 2025, Acumed announced completion of the first wrist fixation case using Acu-Loc NEXT, an update of the original Acu-Loc system.
Mid-Tier Players Building a Base
Globus Medical and Enovis are among the largest players in orthopedics, but until recently had very little representation in the trauma market. According to our estimates, both companies surpassed $100 million in trauma sales in 2025.
Globus Medical’s legacy trauma offering is about 80% complete, and benefited from the addition of NuVasive’s NSO products. Enovis experienced slowing foot and ankle volumes last year but noted signs of a rebound starting in the third quarter.
“Our trauma business delivered approximately 27% growth in Q4 versus the prior year quarter, driven by continued uptake of our legacy trauma line as well as our precise limb lengthening products,” said Globus Medical CEO Keith Pfeil. “Looking back on 2025, our strategy of focusing on Level 1 and Level 2 trauma centers has shown results, coupled with meaningful product launches.”
Large and medium-sized orthopedic companies are seeing success as they expand their presence in the trauma market. Arthrex and Orthofix are additional examples. We expect companies to continue to focus on trauma portfolio opportunities that are synergetic with their other offerings.
Rise in Non-Metal Implants
Bio-integrative and absorbable implants are experiencing greater market adoption. Companies like OSSIO and Bioretec have improved the weight-bearing strength and degradation process of their implant materials, creating opportunities for patients’ fractures to heal without the need for long-term metal implants.
Advancements in this technology could be meaningful for pediatric and young adult patients, who often undergo a second surgery to have their metal screws removed after their fractures heal.
“If you look at the sales trajectory of trauma, or orthopedics in general, market factors like an aging population are influencing growth. However, the CAGR for most of these markets is not astoundingly high. Absorbables, however, are achieving double-digit growth,” said Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec.
Filling Gaps in Niche Indications
Smaller companies are entering the market with novel technologies that address the needs of patients undergoing more complex procedures or those with high revision rates. Specifically, pelvis and hip fractures are on the rise as the population ages, and these patients could benefit from improved implant offerings.
For example, CurvaFix recently received FDA clearance for its Low Profile System, a percutaneous solution for the fixation of pelvic fractures. Hyprevention received Breakthrough Device Designation for its Y-STRUT Hip Implant for patients with cancer presenting with bone metastasis or lesions in the proximal femur.
We estimate the trauma segment generated $9.6 billion in worldwide sales during 2025, growing 5.8% compared to the prior year. The segment makes up 15% of the overall orthopedic market.
For the second consecutive year, core trauma exceeded expectations, while procedure volume softness impacted the foot and ankle segment. We expect those...
We estimate the trauma segment generated $9.6 billion in worldwide sales during 2025, growing 5.8% compared to the prior year. The segment makes up 15% of the overall orthopedic market.
For the second consecutive year, core trauma exceeded expectations, while procedure volume softness impacted the foot and ankle segment. We expect those two factors to normalize over the coming years but to continue driving mid-single digit growth through 2029.
Below we take a look at 2025 company performance, how companies new to the trauma space are building a base of business, the rise of non-metal implants and ways that companies are filling gaps in niche areas.
Company Performance
Trauma is an extremely consolidated market. Stryker and J&J MedTech are the top two players, accounting for 60% of global sales.
Johnson & Johnson MedTech’s trauma business is more than three times larger than the next largest player, Zimmer Biomet, which benefited from the early-2025 acquisition of Paragon 28. Smith+Nephew and Acumed round up the market’s top five players, who account for a combined 80% of the market.
Like other players in the foot and ankle market, Stryker had a softer year for sales. However, the company’s success in core trauma more than offset the slowdown in foot and ankle. The Pangea Plating System not only drove sales growth but also increased customer awareness of Stryker’s broad trauma offering.
DePuy Synthes’ trauma product growth improved each quarter, with the second half of the year performing far stronger than the first. International sales and the VOLT Plating System were key growth drivers.
Among mid-tier companies, Zimmer Biomet worked through its Paragon 28 integration during 2025. The company had to address “contract friction” but remains bullish on the long-term growth prospects for the business.
“I wanted to buy a company that had innovation today, but a pipeline for tomorrow,” said Zimmer Biomet CEO Ivan Tornos. “We are stabilizing some of the early contract friction that you can see in this category. We continue to see great momentum with commercial execution and launching new products. We think of this asset as something that needs to be growing in double digits for a period of time. There may be some hiccups every once in a while. But overall, the organic growth of Paragon 28 should remain in the teens.”
Smith+Nephew saw good growth from the EVOS plating system, which was partially offset by slower sales of legacy systems. In late 2025, Acumed announced completion of the first wrist fixation case using Acu-Loc NEXT, an update of the original Acu-Loc system.
Mid-Tier Players Building a Base
Globus Medical and Enovis are among the largest players in orthopedics, but until recently had very little representation in the trauma market. According to our estimates, both companies surpassed $100 million in trauma sales in 2025.
Globus Medical’s legacy trauma offering is about 80% complete, and benefited from the addition of NuVasive’s NSO products. Enovis experienced slowing foot and ankle volumes last year but noted signs of a rebound starting in the third quarter.
“Our trauma business delivered approximately 27% growth in Q4 versus the prior year quarter, driven by continued uptake of our legacy trauma line as well as our precise limb lengthening products,” said Globus Medical CEO Keith Pfeil. “Looking back on 2025, our strategy of focusing on Level 1 and Level 2 trauma centers has shown results, coupled with meaningful product launches.”
Large and medium-sized orthopedic companies are seeing success as they expand their presence in the trauma market. Arthrex and Orthofix are additional examples. We expect companies to continue to focus on trauma portfolio opportunities that are synergetic with their other offerings.
Rise in Non-Metal Implants
Bio-integrative and absorbable implants are experiencing greater market adoption. Companies like OSSIO and Bioretec have improved the weight-bearing strength and degradation process of their implant materials, creating opportunities for patients’ fractures to heal without the need for long-term metal implants.
Advancements in this technology could be meaningful for pediatric and young adult patients, who often undergo a second surgery to have their metal screws removed after their fractures heal.
“If you look at the sales trajectory of trauma, or orthopedics in general, market factors like an aging population are influencing growth. However, the CAGR for most of these markets is not astoundingly high. Absorbables, however, are achieving double-digit growth,” said Sarah van Hellenberg Hubar-Fisher, CEO of Bioretec.
Filling Gaps in Niche Indications
Smaller companies are entering the market with novel technologies that address the needs of patients undergoing more complex procedures or those with high revision rates. Specifically, pelvis and hip fractures are on the rise as the population ages, and these patients could benefit from improved implant offerings.
For example, CurvaFix recently received FDA clearance for its Low Profile System, a percutaneous solution for the fixation of pelvic fractures. Hyprevention received Breakthrough Device Designation for its Y-STRUT Hip Implant for patients with cancer presenting with bone metastasis or lesions in the proximal femur.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
